- Indianapolis drugmaker Eli Lilly on Monday disclosed more details about the effects of rebates and discounts on pricing, in what has become an increasingly common move among drugmakers to address concerns over the high costs of prescription drugs.
- In its 2016 Lilly Integrated Summary Report, the company said average net price increases for its U.S. product portfolio were only 2.4% last year, even though list prices — which don’t include discounts or rebates given to payers — jumped by 14%.
- Merck, Johnson & Johnson and other big pharmas have made similar efforts towards transparency, detailing the differences between list and net prices. While opening up the black box of drug prices some, the moves also help shift blame for high drug costs onto the convoluted workings of the current insurance system.
Read complete article here: